公开(公告)号：US10702542B2

公开(公告)日：2020-07-07

申请号：US16395929

申请日：2019-04-26

申请人： KALEIDO BIOSCIENCES, INC.

发明人： Geoffrey A. von Maltzahn ,  Jared Silverman ,  Yvonne J. Yamanaka ,  John Miles Milwid ,  John M. Geremia

IPC分类号： A61K31/702 ,  A61K45/06 ,  A61K31/716 ,  A61K31/733 ,  A61P1/00 ,  A61K31/09 ,  A61K31/11 ,  A61K31/12 ,  A61K31/165 ,  A61K31/34 ,  A61K31/353 ,  A61K31/365 ,  A61K31/366 ,  A61K31/7034 ,  A61K31/7048 ,  A61K31/706 ,  A61K31/715 ,  A23L33/10 ,  A23P10/00 ,  A61K31/7004 ,  A61K31/7016 ,  A61K35/741 ,  A61K35/00

摘要： Preparations of glycan therapeutics, pharmaceutical compositions and medical foods thereof, optionally comprising micronutrients, polyphenols, prebiotics, probiotics, or other agents are provided and methods of making same. Also provided are methods of using said glycan therapeutics, e.g. for the modulation of human gastrointestinal microbiota and to treat dysbioses.

公开(公告)号：US20200078385A1

公开(公告)日：2020-03-12

申请号：US16680054

申请日：2019-11-11

申请人： ABBOTT LABORATORIES

发明人： JoMay Chow ,  Steven R. Davis ,  Rachael Buck ,  Geralyn O. Duska-McEwen ,  Hawley K. Linke

IPC分类号： A61K31/702 ,  A23L33/00 ,  A61K31/716 ,  A61K45/06 ,  A23L33/10 ,  A23L33/12 ,  A23L33/19 ,  A23L33/135 ,  A61K9/107 ,  A61K31/733 ,  A61K35/20 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K36/48 ,  A61K38/01

摘要： Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.

公开(公告)号：US20200054690A1

公开(公告)日：2020-02-20

申请号：US16603318

申请日：2018-04-10

申请人： KIBOW BIOTECH, INC.

发明人： Natarajan Ranganathan

IPC分类号： A61K35/742 ,  A61K36/06 ,  A61K31/716 ,  A61K31/733 ,  A23L33/14 ,  A23L33/135 ,  A23L33/21

摘要： A composition composed of xylooligosaccharide, arabinogalactan, inulin, Ganoderma lucidum beta glucan, insoluble yeast β (1, 3/1, 6)-glucan, soluble oat β (1,3/1, 4)-glucan, and insoluble dried Saccharomyces cerevisiae fermentate, with a Bacillus coagulans component, for use in improving or maintaining digestive health, weight and glucose balance and boosting immunity is provided.

公开(公告)号：US20200030360A1

公开(公告)日：2020-01-30

申请号：US16466927

申请日：2017-12-05

申请人： Innate Biotherapeutics, LLC

发明人： Gabriel Oscar Reznik ,  John James Kane ,  James Michael Siedlecki ,  Zuzana Dostalova ,  Isabelle Sansal-Castellano ,  Ifat Rubin-Bejerano ,  Hua Miao ,  Eric Steven Furfine

IPC分类号： A61K31/716 ,  A61K47/61 ,  C07K16/28 ,  C07K16/32

摘要： The present invention encompasses embodiments in which a therapeutic antibody is conjugated to β-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more β-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such β-1,6-glucan conjugates. In certain embodiments, a β-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.

公开(公告)号：US20200023024A1

公开(公告)日：2020-01-23

申请号：US16158652

申请日：2018-10-12

申请人： GeneFerm Biotechnology Co., Ltd.

发明人： JINN-DER JIN

IPC分类号： A61K36/074 ,  A61K31/716 ,  A61K47/12 ,  A61K47/22 ,  A61P37/02

摘要： A Ganoderma lucidum polysaccharides composite composition comprising, based on a total composition: 1 to 5 wt. % β-glucan extract, 1 to 5 wt. % Ganoderma lucidum mycelium extract, 1 to 5 wt. % Trametes versicolor mycelium extract, 1 to 5 wt. % Tremella fuciformis Berk extract, 1 to 5 wt. % Auricularia auricula-judae extract, 1 to 5 wt. % Hericium erinaceus extract, 1 to 3 wt. % Ganoderma lucidum fruiting body extract, and water.

公开(公告)号：US20190262381A1

公开(公告)日：2019-08-29

申请号：US16290699

申请日：2019-03-01

申请人： KEMIN INDUSTRIES, INC.

发明人： Jeffrey Richard LeBrun ,  Robert Levine ,  Geoffrey Paul Horst

IPC分类号： A61K31/716 ,  A23K50/60 ,  A61K45/06 ,  A23K20/163 ,  A23K50/10

摘要： Immune function of an animal can be modulated by administration of a composition that includes beta glucan. The beta glucan can be derived from Euglena, which provides a form of beta glucan that is different from other organisms, where the beta glucan is predominantly unbranched beta-(1,3)-glucan. Beta glucan can also be complexed with a metal, such as zinc, and/or can combined with an animal feed component to form an animal feed composition. Use of such compositions can improve the well being of an animal, and may augment or even replace the use of antibiotics in certain circumstances.

公开(公告)号：US20190216866A1

公开(公告)日：2019-07-18

申请号：US16249156

申请日：2019-01-16

申请人： BEIJING SCITOP BIO-TECH CO.,LTD

发明人： Jianjun ZHANG ,  Chen MA ,  Jicheng WANG

IPC分类号： A61K35/747 ,  A61K35/745 ,  A61K9/14 ,  A61K31/702 ,  A61K31/716 ,  A61K36/45 ,  A61K36/73 ,  A61P1/00 ,  A61P11/00 ,  A61P31/00

CPC分类号： A61K35/747 ,  A61K9/14 ,  A61K31/702 ,  A61K31/716 ,  A61K35/745 ,  A61K36/45 ,  A61K36/73 ,  A61P1/00 ,  A61P11/00 ,  A61P31/00

摘要： Provided are a composite probiotic lactic acid bacteria powder and a preparation method and use thereof, the composite probiotic lactic acid bacteria powder can be composited from Lactobacillus casei Zhang bacteria powder, Bifidobacterium animalis V9 bacteria powder, Lactobacillus plantarum P8 bacteria powder, Lactobacillus plantarum C2 bacteria powder, with prebiotics and fruit-vegetable powder. The composite probiotic lactic acid bacteria powder has a significantly protective effect against irritable bowel syndrome, oral infection and nasal cavity infection, and can prevent the occurrence of upper respiratory tract infection, at the same time, it can improve gastrointestinal symptoms, regulate gut microbiota and improve the body's immunity.

公开(公告)号：US10335429B2

公开(公告)日：2019-07-02

申请号：US15483270

申请日：2017-04-10

申请人： Generale Biscuit

发明人： Isabel Moreira De Almeida ,  Alexandra Meynier ,  Maria Urbieta

IPC分类号： A61K31/717 ,  A21D13/047 ,  A21D13/40 ,  A21D13/02 ,  A61K31/716 ,  A21D13/04 ,  A61K36/8998 ,  A23L7/10 ,  A23L33/105 ,  A23L33/21 ,  A23L33/22 ,  A21D13/38 ,  A21D13/32 ,  A21D13/80 ,  A61K9/00 ,  A61K36/899

摘要： The present invention relates to an association of beta-glucans from a first cereal and arabinoxylans from a second cereal different from the first cereal, and their use to improve the microbiota balance in human gut.

公开(公告)号：US20190142862A1

公开(公告)日：2019-05-16

申请号：US16308701

申请日：2017-06-09

申请人： OTSUKA PHARMACEUTICAL FACTORY, INC.

发明人： Kazuo HINO ,  Naoyuki ENDO ,  Sho MIYATAKE

IPC分类号： A61K31/732 ,  A61P3/02 ,  A61K9/08 ,  A23L33/125 ,  A61P1/12 ,  A23L33/16 ,  A61K31/716 ,  A61K38/17 ,  A61K33/42 ,  A61K36/899 ,  A61K31/715

CPC分类号： A61K31/732 ,  A23L33/10 ,  A23L33/125 ,  A23L33/16 ,  A23V2002/00 ,  A61K9/08 ,  A61K31/215 ,  A61K31/70 ,  A61K31/715 ,  A61K31/716 ,  A61K33/00 ,  A61K33/42 ,  A61K35/12 ,  A61K35/60 ,  A61K36/28 ,  A61K36/286 ,  A61K36/31 ,  A61K36/63 ,  A61K36/899 ,  A61K38/02 ,  A61K38/1709 ,  A61P1/12 ,  A61P3/02 ,  A61P43/00

摘要： It is an object of the present invention to provide a nutritional composition for preventing diarrhea enabling ingestion or administration of nutritional ingredients while effectively preventing diarrhea, and is capable of stably keeping the viscosity when stored in a liquid form. A nutritional composition that is prepared by selecting a pectin having a degree of esterification of 10 to 30%, a degree of amidation of 0 to 25%, and a degree of free acids of 64% or more and less than 85% among pectins, and mixing the selected pectin with lipid, carbohydrate and protein, enables ingestion or administration of nutritional ingredients while effectively preventing diarrhea, and is capable of stably keeping the viscosity when stored in a liquid form.

公开(公告)号：US20180369376A1

公开(公告)日：2018-12-27

申请号：US16118909

申请日：2018-08-31

申请人： Biothera, Inc.

发明人： William J. Grossman ,  Mary A. Antonysamy ,  Richard M. Walsh ,  Mariana I. Nelson ,  Nandita Bose ,  Michael E. Danielson ,  Kyle S. Michel

IPC分类号： A61K39/395 ,  A61K31/716 ,  G01N33/569 ,  G01N33/554 ,  C07K16/14 ,  A61K39/39 ,  A61K47/68 ,  A61K45/06 ,  C07K16/12 ,  A61K39/00

摘要： This disclosure describes, in one aspect, a composition that includes a β-glucan component and an antibody component that specifically binds to the β-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to β-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of β-glucan and administering to the subject a composition that comprises a β-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.